In a major AI acquisition, Anthropic buys Coefficient Bio to revolutionize drug discovery and healthcare research.
Anthropic has reportedly secured a new asset to strengthen its position in the healthcare sector. The AI giant has purchased the stealth biotech startup, Coefficient Bio.
Reports from The Information and Eric Newcomer value this transaction at a staggering $400 million. The deal was struck entirely in stock. While sources close to the situation confirmed the closure of the deal to TechCrunch, they chose to remain silent on the specific financial figures.
This move is a strategic step for Anthropic. It comes shortly after the company revealed its plans for "Claude for Life Sciences" back in October. The tool was designed to assist researchers in making new scientific discoveries. Buying Coefficient Bio fits perfectly into this bigger picture.
Interestingly, Coefficient Bio is a very young company. It was launched only eight months ago. Despite being a startup, it was founded by two experienced names in the industry, Samuel Stanton and Nathan C. Frey. Both founders previously worked in computational drug discovery at Genentech’s Prescient Design. Their goal was simple: use AI to make drug discovery faster and more efficient.
The acquisition also involves talent. The small team of about ten people from Coefficient Bio is set to join Anthropic. They will become part of the health and life science team. This purchase shows that Anthropic is serious about mixing AI with biological research. It is a clear signal of where the future of tech is heading.
0 Comments